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Background: Bronchial carcinoids are pulmonary neuroendocrine cell-derived tumors comprising typical (TC) and
atypical (AC) malignant phenotypes. The 5-year survival rate in metastatic carcinoid, despite multiple current
therapies, is 14-25%. Hence, we are testing novel therapies that can affect the proliferation and survival of bronchial
carcinoids.
Methods: In vitro studies were used for the dose–response (AlamarBlue) effects of acetazolamide (AZ) and
sulforaphane (SFN) on clonogenicity, serotonin-induced growth effect and serotonin content (LC-MS) on H-727 (TC)
and H-720 (AC) bronchial carcinoid cell lines and their derived NOD/SCID mice subcutaneous xenografts. Tumor
ultra structure was studied by electron microscopy. Invasive fraction of the tumors was determined by matrigel
invasion assay. Immunohistochemistry was conducted to study the effect of treatment(s) on proliferation (Ki67,
phospho histone-H3) and neuroendocrine phenotype (chromogranin-A, tryptophan hydroxylase).
Results: Both compounds significantly reduced cell viability and colony formation in a dose-dependent manner
(0–80 μM, 48 hours and 7 days) in H-727 and H-720 cell lines. Treatment of H-727 and H-720 subcutaneous
xenografts in NOD/SCID mice with the combination of AZ + SFN for two weeks demonstrated highly significant
growth inhibition and reduction of 5-HT content and reduced the invasive capacity of H-727 tumor cells. In terms
of the tumor ultra structure, a marked reduction in secretory vesicles correlated with the decrease in 5-HT content.
Conclusions: The combination of AZ and SFN was more effective than either single agent. Since the effective
doses are well within clinical range and bioavailability, our results suggest a potential new therapeutic strategy for
the treatment of bronchial carcinoids.
Keywords: Bronchial carcinoids, Pulmonary neuroendocrine tumor, Serotonin, Carbonic anhydrase, Acetazolamide,
Sulforaphane* Correspondence: hermie@sickkids.ca
1Developmental and Stem Cell Biology, University of Toronto, Toronto, ON,
Canada
3Department of Paediatric Laboratory Medicine, The Hospital for Sick
Children, Institute of Medical Science, University of Toronto, Toronto, ON,
Canada
Full list of author information is available at the end of the article
© 2013 Bayat Mokhtari et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Bayat Mokhtari et al. BMC Cancer 2013, 13:378 Page 2 of 18
http://www.biomedcentral.com/1471-2407/13/378Background
Bronchial carcinoid tumors are a group of neuroendo-
crine tumors (NETs), which constitute roughly 1–2% of
all lung malignancies in the adult population and
account for 31% of all cases of carcinoids [1]. These
tumors are classified as typical (TC) and atypical (AC).
The 5-year survival rate is 98% for TC and 76% for AC
[2]. Furthermore, it is thought that tumor-derived 5 hy-
droxytryptamine (5-HT), or serotonin, causes carcinoid
syndrome manifested by skin flushing, excessive diar-
rhea, right-sided heart disease and bronchoconstriction.
Nearly 95% of patients present with right-sided heart
valve disease and are associated with poor long-term
survival, with death occurring in approximately one-
third of these patients. Patients with liver metastases
may develop malignant carcinoid syndrome, releasing
vasoactive substances into the systemic circulation. Cur-
rently, severe carcinoid syndrome is effectively managed
with octreotide and lanreotide, which are somatostatin
analogs [3]. However, metastatic bronchial carcinoids are
incurable and the 5-year survival rate is 20-30% [4].
Conventional cytotoxic agents such as fluorouracil,
doxorubicin and cyclophosphamide, which are effective
in the treatment of other neoplasms, have been ineffect-
ive against carcinoids [5]. Therefore, strategies that tar-
get the survival pathways of pulmonary carcinoids are
being considered to treat carcinoids. In the present
study, we have investigated the efficacies of two drugs,
acetazolamide (AZ) and sulforaphane (SFN), which are
known to target the survival pathways in other cancers.
AZ is a classic pan-carbonic anhydrases (CAs) inhibitor.
CAs help tumor cells to cope with acidic and hypoxic
stress by reversible hydration of carbon dioxide to proton
and bicarbonate [6], thereby maintaining physiological
intracellular pH, despite the acidic extracellular environ-
ment. The overexpression of CAs has been reported in a
wide variety of human neoplasms and is associated with
poor prognosis in many types of cancers, such as breast
adenocarcinoma and bladder carcinoma [7,8]. High ex-
pressions of HIF-1α and CAs have been reported in ileal
carcinoids [9]. Since CAs are a major component of sur-
vival pathways of tumor cells, the inhibition of enzymatic
activity of CAs has been studied extensively as a thera-
peutic strategy against cancer [10]. Chemical inhibitors of
CAs (CAIs) such as AZ and AZ-based new compounds as
single agent or combination therapy with synthesized
aromatic sulfonamides such as 2-(4-sulfamoylphe- nyl-
amino)-4,6-dichloro-1, 3, 5-triazine (TR1) and 4-[3-(N, N-
dimethylaminopropyl) thioreidophenylsulfonylaminoethyl]
benzenesulfonamide (GA15) with high affinity for CA9
have been shown to inhibit CA9 enzymatic activity and
suppress the invasive capacity, decrease cell proliferation
and induce apoptosis in human renal carcinoma and cer-
vical cancer cells [11,12].5-HT is another crucial factor contributing to the de-
velopment of NETs, including human pancreatic carcin-
oid cells [13]. Previous studies have demonstrated that
5-HT stimulates the proliferation of lung carcinoid cell
lines [14] and it can function as an autocrine growth fac-
tor for carcinoids (and NETs) [14]. We have proved that
hypoxia stimulates the release of 5-HT from neuroepi-
thelial bodies, the precursor cells of bronchial carci-
noids, and that the blockade of 5-HT3 receptor inhibits
hypoxia-induced 5-HT release [15]. We investigated
whether our treatments could reduce the production of
5-HT in the tumors, this being relevant to the patho-
physiology of the carcinoid syndrome and auto regula-
tory growth. The inhibition of CAs, which regulate
intracellular and extracellular pH, can severely abrogate
homeostatic and neuroendocrine functions [16,17].
Previously, the inhibitory effects of AZ on 5-HT secre-
tion and proliferation in rabbit conjunctival epithelium
and human renal carcinoma cells have been reported
[12,16,17]. Therefore, we hypothesize that AZ will down
regulate the secretion of 5-HT and reduce cell viability.
Furthermore, we reasoned that combinatorial treat-
ment of CA inhibitors with other agents that target sur-
vival pathways would enhance the efficacy of AZ. In this
regard, SFN, known to demonstrate anticancer proper-
ties by several mechanisms, is a reasonable candidate.
The anticancer mechanisms of SFN include the inhib-
ition of survival pathways, induction of proapoptotic
pathways, inhibition of histone deacetylases (HDAC)
and induction of Phase-II antioxidant enzymes. The
oncogenic pathways affected by SFN are Akt (ovarian
cancer) and Wnt/beta catenin (breast cancer) [18-20],
whereas, beta catenin accumulation in gastro-intestinal
carcinoid cells and the role of PI3K/Akt signaling in
pulmonary carcinoids have been established [20,21]. SFN
is reported to affect survival pathway by hyperphospho-
rylation of Rb protein (anti-apoptotic in un-phosphory-
lated form) in colon cancer cells, and has inhibited
cyclin D1 in pancreatic cancer cells [22,23], whereas,
cyclin D1-induced Rb overexpression has been found to
be upregulated in pulmonary carcinoids [24]. SFN is also
an inhibitor of HDAC [25], and other HDAC inhibitors
such as valproic acid and suberoyl bis-hydroxamic acid
in combination with lithium have demonstrated signifi-
cant growth inhibition and cell cycle arrest in H-727
cells [26]. SFN has demonstrated synergistic activity with
cytotoxic agents (5-fluorouracil, paclitaxel), phytochemi-
cals (resveratol) and targeted therapies (sorafenib,
imatinib) [27-30].
In terms of the involvement of 5-HT in bronchial car-
cinoids, SFN can be an appropriate agent for carcinoid
therapy as it has been reported to reduce the expression
of 5-HT receptors including 5-HT2, 5-HT3 and sero-
tonin transporter (SERT) as well as to affect the release
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potentially demonstrate antitumor activity and demon-
strate an additive or synergistic effect with AZ in pul-
monary carcinoids given the (1) findings that SFN, in
other cancers, can target survival pathways which also
contribute to the survival and progression of carcinoids,
(2) effect of SFN on 5-HT pathway, and (3) the synergis-
tic activity of SFN with other anticancer agents. Since
both AZ and SFN can potentially affect the survival
mechanisms of pulmonary carcinoids by different mech-
anisms, we hypothesize that the combination of these
two compounds can demonstrate additive or synergistic
effect against pulmonary carcinoids. Since SFN down
regulates the expression of 5-HT receptors [31], the
combination of AZ + SFN might be able to shut down
5-HT-mediated autocrine growth of carcinoid cells.
In the present study, we report our finding that both
AZ and/or SFN have inherent antitumor activity and the
combination of these agents demonstrates significantly
higher antitumor activity in in vitro and in vivo models
of bronchial carcinoid (BC).
Methods
Drug, reagents and supplements
Acetazolamide (AZ), dimethyl sulfoxide (DMSO),
serotonin hydrochloride (5-HT), D4-serotonin, 5-
Hydroxyindole-3-acetic acid (5-HIAA) and trans-2-
phenylcyclopropylamine hydrochloride were obtained
from Sigma-Aldrich (Oakville, ON, Canada). Sulforaph-
ane (SFN) was purchased from LKT Laboratories (St.
Paul, MN, USA). RPMI-1640 and EMEM medias, fetal
bovine serum (FBS) and penicillin-streptomycin, were
purchased from Gibco (Burlington, ON, Canada) and
bovine serum albumin (BSA) was obtained from
Invitrogen (Grand Island, NY, USA). Matrigel was pur-
chased from BD Biosciences company (La Jolla, CA,
USA). Methylcellulose was obtained from MethoCult
company (Vancouver, BC, Canada). Phosphate-buffered
Saline (PBS) was purchased from Multicell (St. Bruno,
QC, Canada).
Cell lines
The lung carcinoid cell lines, well differentiated H-727
(TC) and poorly differentiated H-720 (AC), were pur-
chased from the American Type Culture Collection
(ATCC). Fetal lung fibroblast (FLF) strain, available in
our cell bank was used as a normal control.
Cell culture
The lung carcinoid and fetal lung fibroblast cell lines
were maintained in RPMI-1640 and EMEM, respectively.
The medias were supplemented with 10% heat-
inactivated FBS, 100 IU/ml and penicillin, 100 ug/ml
streptomycin at 37.0°C, 5% CO2. We tested the effect ofvarying concentrations of FBS (0-20%) on the prolifera-
tion of H-727 and H-720 cells to determine the
minimum percentage of FBS needed for cell survival for
an experiment of 7 days. The cells were plated in
48-well black walled plates (Falcon) at 20,000 cells/well
and incubated overnight (37°C and 5% CO2). Fresh
supplemented media including the different percentages
(1-20%) of FBS were added every other day for a period
of seven days.Animals
Four-to-six-week-old female NOD/SCID mice were
obtained from the animal facility at The Hospital for Sick
Children (SickKids) and used for our in vivo study within
the guidelines of the Lab Animal Services. The protocols
for animal experimentation were approved by the Animal
Safety Committee, Sickkids Research Institute.Trypan blue exclusion assay
Trypan blue exclusion assay was used to assess cell via-
bility. Following the indicated treatments, cells were
trypsinized and incubated with trypan blue (Multicell,
Wisent Inc. St. Bruno, QC, Canada) (final volume 20%
added to media) for 10 minutes at 37°C. Percent viability
was calculated as the number of trypan blue positive per
total cells counted per microscopic field (total of 4 fields
per condition).AlamarBlue cytotoxicity assay
Cells were seeded (5,000 and 20,000 cells) in 48-well
plates in complete medium. After 48 hours, cells were
treated with AZ and/or SFN for 48 hours and 7 days.
The highest concentration of DMSO (2 × 10-4) was used
as the vehicle control. AlamarBlue (AbD Serotec,
MorphoSys, Raleigh, NC, USA) agent (10% of total vol-
ume) was added to each well for 4 hours before fluoro-
metric detection. Fluorescence was measured using the
SPECTRAmax Gemini Spectrophotometer at excitation
wavelength of 540 nm and emission wavelength of 590 nm.
Percent survival vs. control is reported as the mean +/−
standard deviation.Effect of 5-HT on growth of lung carcinoid cells
AlamarBlue assay was performed to determine whether
AZ and/or SFN could block the effects of 5-HT on
H-727 and H-720 growth. Cells were treated for 7 days
with AZ and/or SFN (0–80 μM) after adding 5-HT ex-
ogenously (0.01 nM for H-727 and 10 nM for H-720)
into the supplemented media (2.5% FBS). Trans-2-
phenylcyclopropylamine hydrochloride, a monoamine
oxidase inhibitor (MAOI), (2 μM) was added to prevent
metabolism of 5-HT during the experiment [32,33].
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Invasion assay was performed as previously described
[34]. Eight um pore size polyvinyl membrane-based
chambers (Corning Life Sciences, Lowell, MA, USA)
were coated with 100 μl of ice-cold matrigel. The
matrigel-coated chambers were incubated at 37°C for 4
hours, after which 30,000 cells were added to the upper
chamber. Five hundred μl RPMI-1640 media were filled
in the lower chamber. The whole system was incubated
at 37°C for 24 hours. The top part of the incubated
chamber was then removed and invading cells were
counted following crystal violet staining.
Methylcellulose clonogenic assay
H-727 and H-720 cells were treated with varying con-
centrations (10 μM, 20 μM and 40 μM) of AZ and/or
SFN in a medium supplemented by 10% FBS for 7 days
every other 48 hours. To assess the clonogenic potential
of treated cells, at the end of the seventh day, cells were
trypsinized and resuspended (3 × 104 cells/ml) in 40%
methylcellulose supplemented with RPMI-1640, 10%
FBS and 1% antibiotics (100 IU/ml penicillin and 100
μg/ml streptomycin) and plated in 35 mm tissue culture
dishes (Nalgene Nunc International, Rochester, NY,
USA) in triplicate and incubated in 5% CO2 at 37°C.
After two weeks, the numbers of colonies were counted
by using a grading dish on a phase contrast microscope
(×10). Clonogenicity was determined as the average of
number of colonies per dish for each treatment group.
In vivo efficacy of AZ and SFN
H-727 and H-720 cells (2 × 106) were injected into the
subcutaneous inguinal fat pad of NOD/SCID mice.
When the tumors attained a diameter of 0.5 cm, the
mice were randomized into 4 groups (5 mice per group).
The control and treatment groups received intraper-
toneal injections of either vehicle (PBS) or AZ (20 mg/
kg) and/or SFN (40 mg/kg), respectively, every day for
two weeks. Experiment was terminated when tumor
sizes exceeded 2 cm2 in diameter or animals showed
signs of morbidity. Tumor diameters were measured on
a daily basis until termination. The long (D) and short
diameters (d) were measured with calipers. Tumor
volume (cm3) was calculated as V = 0.5 × D × d2. After
euthanizing the mice, the tumors were resected,
weighted and fixed in 10% neutral-buffered formalin at
room temperature and processed for histopathology.
Electron microscopic analysis
Tumor fragments were fixed in 4% formaldehyde and
1% glutaraldehyde in phosphate buffer, pH 7.4, and post
fixed in 1% osmium tetroxide. Tumor tissues were then
dehydrated in a graded series of acetone from 50 to
100% and subsequently infiltrated and embedded inEpon-Araldite epoxy resin. The processing steps from
post fixation to polymerization of resin blocks were car-
ried out in a microwave oven, Pelco Bio Wave 34770
(Pelco International, Clovis, CA, USA) using similar pro-
cedures but with a slight modification as recommended
by the manufacturer. Ultrathin sections were cut with a
diamond knife on the Reichert Ultracut E (Leica Inc.,
Vienna, Austria). Sections were stained with uranyl acet-
ate and lead citrate before being examined in the JEM-
1011 (JEOL USA, Inc., Peabody, MA, USA). Digital elec-
tron micrographs were acquired directly with a 1024 ×
1024 pixels CCD camera system (AMT Corp., Danvers,
MA, USA) attached to the ETM (1200 EX electron
microscope).
Immunofluorescence methods
Frozen sections (5 μm) were immersed in precooled
acetone at −20°C for 10 minutes and allowed to dry at
room temperature for 20 minutes; sections were washed
in double distilled water. Antigen retrieval was perfor-
med by heating in a microwave for 14 minutes in tri-
sodium citrate buffer (pH 6.0). To block non-specific
binding, sections were treated with 4% BSA for 30 mi-
nutes. The sections were incubated with primary anti-
bodies at 4°C overnight. The primary antibodies used as
follow: anti-chromogranin A (Dako, Carpinteria, CA,
USA), anti-ki67 (Dako, Carpinteria, CA, USA) and anti-
phospho-Histone H3 (Temecula, CA, USA). After this
overnight incubation, primary antibodies incubation sec-
tions were washed with PBS 3 × 10 minutes each at RT
and bound primary antibodies were detected using sec-
ondary antibodies diluted in 4% BSA. Sections were
incubated for 1 hour in secondary antibody-donkey anti-
goat (Abcam, Cambridge, MA, USA) and chicken anti-
rabbit (Invitrogen, Grand Island, NY, USA) at RT.
Finally, sections were washed in PBS 3 × 10 minutes
each and mounted with VectaShield (Dako, Carpinteria,
CA, USA) mounting medium with DAPI (4′,6-
diamidino-2-phenylindole; Sigma-Aldrich, St. Louis,
MO, USA). For negative control, sections were incu-
bated in secondary antibodies only. Mounted slides were
visualized using a fluorescence microscope at × 10 and ×
40 magnification (Nikon DXM1200 digital camera,
NortonEclipse software version 6.1). For quantification,
the percentage of positive cells was calculated using the
formula [X (6 low power fields of positive staining)/Y
(total count per 6 fields) × 100]. The level of immuno-
fluorescence (IF) of the positive cells was also examined
by ImageJ64 software.
Immunohistochemistry
Immunohistochemistry (IHC) was performed on paraffin
sections as previously described [35]. After deparaffiniza-
tion through xylene and graded alcohols into water and
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10 mM sodium citrate buffer (pH 6.0) by heating in a
microwave oven for 10 minutes. After cooling the sec-
tions for 20 minutes at room temperature, endogenous
peroxidase activity was blocked by incubation with 3%
hydrogen peroxide in methanol for 10 minutes. After
washing in PBS (pH 7.4) for a further 5 minutes and
blocking non-specific binding by incubating in 3% BSA/
PBS for 10 minutes, the sections were incubated with
monoclonal mouse anti-human Ki-67 antigen/FITC
(MIB-1);(1:50) (DakoCytomation, Glostrup, Denmark) at
4°C overnight. Afterwards, the slides were washed
several times with PBS and incubated at room
temperature with a broad-spectrum poly horseradish
peroxidase (HRP) conjugate as a secondary antibody
(Invitrogen, Zymed, Burlington, ON, Canada). Next, the
slides were washed with PBS several times and stained
with DAB (3, 3′-diaminobenzidine; Vector Laboratories,
Orton Southgate, Peterborough, United Kingdom) for
two minutes. After washing again with PBS, the slides
were then stained with hematoxylin and mounted. Nega-
tive controls included incubation in the relevant second-
ary antibodies only.
Measurement of 5-HT content
To assess the cellular and plasma content of 5-HT and
its metabolite, 5-Hydroxyindoleacetic acid (5-HIAA), we
used a sensitive Liquid Chromatography-Mass Spec-
trometry (LC-MS) method as follows. Samples consis-
ting of calibrators, Quality control (QC), cell pellet or
tissue homogenate were spiked with 2 nm of d4-
serotonin. The mixtures were applied to a Centri-Free
centrifugal filter unit (30,000 MWCO) and centrifuged
at 1000 g for 30 minutes. To 500 μL of calibrator, cell
pellet or tissue homogenate 20 μL of d4-5-HT solution
(100 μΜ) was added. Each sample mixture was vortex-
mixed and transferred to a Centri-Free centrifugal filter
unit (30,000 MWCO) and centrifuged at 1000 g for 30
minutes. The filtrates were transferred to HPLC auto-
sampler vials and a 1 μL aliquot was analyzed by LC-MS.
The LC-MS system consisted of an API4000 QTRAP
mass spectrometer (Applied Biosystems Inc. Foster, CA,
USA) and an Agilent 1200 series HPLC (Agilent Tech-
nologies, USA). 5-HT and 5-HIAA were separated on an
Agilent Eclipse XDB C18 column (100 × 4.6 mm,
1.8 mm). High Performance Liq-Chromatography
(HPLC) mobile phase consisted of A: 2 mmol/L ammo-
nium formate in H2O + 0.1% formic acid and B: 2 mmol/
L ammonium formate in methanol + 0.1% formic acid.
The HPLC flow rate was 800 μL/min and the chromato-
graphic gradient consisted of 90% A increasing to 100%
B in 5 minutes. The mobile phase composition was kept
at 100% B for 2 minutes and subsequently the column
was equilibrated with 90% A for 3 minutes. The massspectrometry was conducted in positive electrospray
ionization mode. The ion transitions of 177.1 →
160.1 m/z, 181.2 → 164.1 m/z, and 192.1 → 146.1 m/z
were monitored for the detection and quantitation of
5-HT, D4-5-HT and 5-HIAA, respectively. The dwell
time for each ion transition was set to 100 msec. The
de-clustering potential and collision energy for 5-HT
and D4-5-HT was set to 36 and 15, and for 5-HIAA at
65 and 20. Data analysis and analyte quantification was
performed using the Analyst software Auto-Quant fea-
ture. The unknown analyte signal was measured against
the calibration curve to obtain the concentration values.
Statistical analysis
Graphing and statistical analysis were performed with
Graph Pad. Unpaired Student’s t-Test and ANOVA soft-
ware were used to obtain the test of significance and in
all analysis the significance levels were specified at p ≤
0.05 (*), p ≤ 0.01 (**), p ≤ 0.001 (***) and p ≤ 0.0001
(****). All in vitro experiments were done in triplicate.
Results
Dose-dependent inhibition of growth of lung carcinoid
and fetal lung fibroblast cell lines with AZ and/or SFN
treatment alone
To determine the effect of AZ and/or SFN treatment on
the growth of H-727 and H-720 cells, AlamarBlue assay
was performed. Both AZ and SFN showed a dose-
dependent inhibitory effect on H-727 and H-720 cells.
Significant growth inhibition of H-727 cells was obtained
after treatment with 40 μM AZ for 48 h. In the case of
SFN, 10 μM concentration caused significant reduction
in growth inhibition of H-727. Whereas 48 h treatment
with AZ did not affect the viability of H-720 at any of
the concentrations, SFN caused significant inhibitory
effect on H-720 at 10 μM after 48 h treatment. After
7 days of treatment, a significant reduction of viability
was seen in H-727 cells and H-720 cells. SFN at the con-
centrations of 5 μM and 10 μM had significant inhibi-
tory effect after 7 days of treatment on H-727 and H-
720, respectively. In comparison to single agents, the
combination of AZ and SFN produced a significant re-
duction in viability of H-727 and H-720 cells at a lower
concentration. After 48 hours, a significant reduction in
viability was seen with a combination of 10 μM of both
AZ and SFN in H-727 and H-720 cells. Seven days of
treatment with 2.5 μM and 10 μM AZ and SFN caused
significant reduction in cell viability of H-727 and H-720
cells, respectively (Figure 1a-f and Table 1). Additionally,
IC50 decreased in both single and combination therapy
in H-727 cells (AZ: 117 μM, SFN: 11 μM and AZ +
SFN: 7 μM) and H-720 cells (AZ: 166 μM, SFN: 25 μM
and AZ + SFN: 18 μM) after 7 days of treatment. The
greater decrease in IC50 for AZ + SFN combination
Figure 1 (See legend on next page.)
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Figure 1 AZ and/or SFN Treatment Inhibit Growth of Lung Carcinoid and Fetal Lung Fibroblast Cells (H-727 and H-720); 48 hours, 7
days) and (FLF): AlamarBlue assay; dose response for AZ, SFN and AZ + SFN; (0-80 μM) treatment in H-727 (a,b and c), H-720 (d, e
and f) cells 48 hours (gray) and 7 days (white) and AlamarBlue assay; dose response for AZ (white), SFN (gray) and AZ + SFN (black);
(0-80 μM) treatment in FLF (g, h and i) cells, 7 days. The significance level compared to control (p value) was specified as follows:
*(p < 0.05), **(p < 0.01), ***(p < 0.001) and ****(p < 0.0001).
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potentiation of SFN effect by AZ (Figure 1, Table 1). The
IC50 of our drugs on normal cells FLF after 7 days of
treatment was 514.4 μM, 39.54 μM and 29.68 μM for
AZ, SFN and AZ + SFN, respectively. A significant re-
duction of viability of FLF cells was seen after 7 days of
treatment with 10 μM AZ, 5 μM SFN and 5 μM AZ +
SFN (Figure 1g-1 and Table 1).
AZ and/or SFN treatment alone inhibit clonogenic ability
of lung carcinoid cell lines
To determine the effect of AZ and/or SFN treatment on
the clonogenicity of H-727 and H-720 cells, methylcellu-
lose clonogenic assay was performed. H-727 and H-720
cells pre-treated for 7 days with AZ and/or SFN at dif-
ferent concentrations showed a dose-dependent inhib-
ition of colony formation relative to untreated cells in
methylcellulose media. Figure 2(a-c) illustrates that the
clonogenic capacity of H-727 and H-720 cells cultured
in methylcellulose was considerably reduced comparedTable 1 Dose-dependent inhibition of growth of lung Carcino
Term (48 hours) and long term (7 days)
Short term Long term




H-727 AZ Min 40 16 +/− 6.2
Max 80 19 +/− 6.2
SFN Min 10 10 +/− 1.1
Max 80 23 +/− 7
AZ+ Min 10 13 +/− 3.4
SFN Max 80 25 +/− 7
H-720 AZ Min - -
Max - -
SFN Min 10 15 +/− 1.6
Max 80 36 +/− 1
AZ+ Min 10 15 +/− 1.5
SFN Max 80 39 +/− 0.7
FLF AZ Min - -
Max - -
SFN Min - -
Max - -
AZ+ Min - -
SFN Max - -to the control. The minimum concentration of AZ was
20 μM for H-727 (10%; p ≤ 0.05) and H-720 (1%; p ≤
0.05). The minimum concentration of SFN was 10 μM
for H-727 (20%; p ≤ 0.01) and H-720 (2%; p ≤ 0.01). The
combination of AZ and SFN significantly reduced
clonogenicity, with 10 μM showing significant reduction
in clonogenicity of H-727 (65%; p ≤ 0.0001) and H-720
(9%; p ≤ 0.0001) Additionally, the combination treat-
ment resulted in a prominent reduction in the
clonogenicity compared to both single agents at 10 μM,
20 μM and 40 μM (p < 0.001) (Figure 2a-c).
AZ and/or SFN treatment inhibited tumor growth in lung
carcinoid cell line xenografts
Tumor morphology
In vivo treatment of mice bearing H-727 and H-720
tumors with AZ and/or SFN showed an inhibitory effect
on tumor growth. In H-727 xenografts, compared to
control, AZ, SFN and AZ + SFN caused 18% (p ≤ 0.05),







5 3 +/− 6.4 117.5
80 35 +/− 3.6
5 17 +/− 2 11.3
80 26 +/− 0.4
2.5 11 +/− 4 6.75
80 98 +/− 0.5
40 15 +/− 4.1 166.5
80 37 +/− 5.1
10 25 +/− 1.6 25.1
80 85 +/− 0.5
10 32 +/− 1.9 18.65
80 90 +/− 0.3
10 8 +/− 1.1 514.4
80 24 +/− 2.8
5 5 +/− 1.2 39.54
80 82
5 13 +/− 2.6 29.68
80 95 +/− 2.4
Figure 2 AZ and/or SFN Treatment Inhibit Clonogenic Ability of Lung Caciniod Cells (H-727 and H-720); (Methylcellulose Clonogenic
Assay; 16 Days): (a and b) phase contrast microscopy (× 10) of H-727 and H-720 colonies in Methylcellulose Clonogenic assay; (c and
d) figures represent the analysis of Methylcellulose Clonogenic assay for H-727 and H-720 colonies for the untreated (black) and
AZ (gray), SFN (white) and AZ + SFN (line pattern), 10 μM, 20 μM and 40 μM; on the day 16th). The significance level compared to control
(p value) was specified as follows: *(p < 0.05), **(p < 0.01), ***(p < 0.001) and ****(p < 0.0001).
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grafts, AZ, SFN and AZ + SFN caused 4.5%, 41% (p ≤ 0.05)
and 65% (p ≤ 0.001) reduction in tumor weights, respect-
ively (Figure 3g, h and i). In H-727 xenografts, the AZ +
SFN combination significantly reduced the weight of
tumors compared to AZ alone (p < 0.0001). IF results
revealed that the number of pHH3 positive cells was re-
duced significantly in all treatment groups compared to
the untreated group, with the AZ + SFN combination in-
ducing 76% (p < 0.0001) and 50% (p < 0.05) reduction in
number of pHH3 positive cells in H-727 and H-720xenografts, respectively. IHC results did not show any
change in the number of Ki67 positive cells (Figure 4a-d).
IF results showed that the levels of chromogranin A (ChA)
(Figure 5a, d) and tryptophan hydroxylase (TPH) (Sigma,
Oakville, ON, Canada) (positive controls: fetal lung tissue;
Figure 6a-e) reduced significantly in all treatment groups
compared to positive controls and untreated groups.
Electron microscopy
Electron microscopy of tumor xenografts revealed cells
with nuclear fragmentation (nu sign), intact nuclei and
Figure 3 (See legend on next page.)
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(See figure on previous page.)
Figure 3 AZ and SFN Inhibit Tumor Progression in Lung Carcinoid Xenografts: figures (a, b, c, d) and (g, h, i , j, k) represent the
volume, morphology, weight, H&E (×10) and ultrastructure (× 104; nu, represents the nucleous and arrow, represent the cytoplasmic
dense-core vesicles) of H-727 and H-720 xenografts, respectively. Figures (f and l) represent the number of dense-core vesicles after
treatment with AZ and/or SFN compare to untreated group in H-727 and H-720 xenografts, respectively.
Bayat Mokhtari et al. BMC Cancer 2013, 13:378 Page 10 of 18
http://www.biomedcentral.com/1471-2407/13/378cell membrane, and a reduction in cytoplasmic dense-
core vesicles (DCV) (arrow sign) in H-727 and H-720
xenografts. In H-727 xenografts, the reduction in the
number of DCV was 33%, 58% and 79% for AZ, SFN
and AZ + SFN treated groups, respectively. In H-720 xe-
nografts, the reduction in the number of DCV was 24%,
48% and 70% for AZ, SFN and AZ + SFN treated
groups, respectively. Compared to the control, AZ, SFN
and AZ + SFN significantly reduced the number of gran-
ules in treatment groups. AZ + SFN treated tumors had
significantly fewer DCV compared to AZ and SFN
treated tumors (Figure 3e and k), Table 2.
AZ and/or SFN treatment affect the invasive fraction of
tumor cells within H-727 xenografts
We used the matrigel invasion assay to determine the in-
vasiveness of cells within the xenografts +/− treatments.
The fraction of invasive cells was 26%, 39% and 69% for
AZ, SFN and AZ + SFN treated tumors compared to un-
treated group, respectively. The AZ + SFN combination
significantly reduced the fraction of invasive cells com-
pared to AZ and SFN (Figure 7a, b), Table 3.
AZ and/or SFN alone treatment reduced 5-HT content of
tumor cells within H-727 and H-720 xenografts
The LC-MS assay revealed that all the treatments re-
duced 5-HT content in the H-727 xenograft model,
whereas only the combination caused significant reduc-
tion in 5-HT content in H720 xenografts. In H-727 xe-
nografts, compared to the control, AZ, SFN and the
combination caused 22%, 14% and 59% reduction in
5-HT content, respectively. In the H-720 model, com-
pared to the control, AZ, SFN and AZ + SFN caused
19%, 19% and 45% reduction in 5-HT content, respect-
ively. Additionally, the combination treatment signifi-
cantly reduced 5-HT content compared to AZ and SFN
treatments for H-727 xenograft cells and SFN treatment
for H-720 xenograft cells (Figure 8a, b), Table 4.
The effect of AZ and/or SFN treatment on 5-HT and
growth of lung carcinoid cell lines
LC-MS measurement proved that FBS contains a con-
siderable amount of 5-HT (9.87 μmol/l). We tested the
effect of varying concentrations of FBS (0-20%) on the
proliferation of H-727 and H-720 cells to determine the
minimum percentage of FBS needed for cell survival for
an experiment lasting 7 days. Results showed that the re-
quired concentration of FBS for cells to survive for theperiod of 7 days was 2.5% (data was not shown). We
then tested the effect of exogenously added 5-HT in the
presence of AZ, SFN and AZ + SFN. As we showed in
Figure 9(a, b), lane 1 contained pure cells suspension
and lanes 2, 3, 4 and 5 contained cells suspension with
vehicle (DMSO), 5-HT (0.01 nM for H-727 and 10 nM
for H-720), MAO-AI (2 μM) and 5-HT + MAOI, re-
spectively. Lanes 6–11 contained cells suspension with
5-HT + MAOI that were diluted in the respective cell
media and applied in final concentrations (AZ and/or
SFN treatment) from 6–11. We found that the AZ +
SFN treatment was highly effective in blocking the
stimulatory growth effects of 5-HT compared to un-
treated cells. Importantly, SFN contributed significantly
to this inhibition. The minimum concentrations of AZ,
SFN and AZ + SFN treatment required to significantly
reduce the 5-HT-induced growth effect was 5 μM (2%,
p < 0.05), 2.5 μM (4%, p < 0.05) and 2.5 μM (3%,
p < 0.05), respectively, for H-727 cells. For H-720 cells,
it was 2.5 μM (5%; p < 0.05), 10 μM (15%; p < 0.0001)
and 10 μM (18%; p < 0.001) for AZ, SFN and AZ + SFN,
respectively. Furthermore, the minimum concentration
of combination treatment required to significantly re-
duce the 5-HT-induced growth effect was 5 μM com-
pared to SFN alone (p = 0.0083) for H-727 cells and 10
μM compared to AZ alone (p = 0.0004) and SFN alone
(p = 0.002) for H-720 cells, (Figure 9a, b).
Discussion
Though carcinoids are slow growing tumors, which can
be treated by surgery, the survival in metastatic carci-
noids is very low because the treatment strategies for
other cancers are not effective for dealing with advanced
stage carcinoids [36]. Therefore, the investigations
concerning the discovery of new strategies for treating
pulmonary carcinoids need to be focused on therapies
that can inhibit the growth and invasiveness of advanced
stage disease. Carcinoid tumors are proving moderately
responsive to newer therapies targeting tumor vascula-
ture and survival pathways [1,2]. The mammalian target
of rapamycin (mTOR) inhibitor, everolimus, has shown
promising initial results alone or combined with other
agents [37-39]. Bronchial AC, which is characterized by
high mTOR expression, has been reported to be re-
sponders to mTOR inhibition, indicating that therapies
targeting the critical survival pathways are potential can-
didates to treat bronchial carcinoids [40]. The evidence
seems to indicate that research for a better therapy for
Figure 4 AZ and SFN Treatment Effect on Mitotic Index and Proliferation in Lung Carcinoid Xenografts: figures (a and b) represent the
mitotic index (pHH3); (arrows), H&E and proliferation (Ki67) in H-727 and H-720 xenografts, respectively; (c and d) represent the
number of pHH3 positive cells for H-727 and H-720 xenografts, respectively, p < 0.05 (*) and p < 0.01(**).
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Figure 5 AZ and SFN Treatment Reduce Chromogranin A in Lung Carcinoid Xenografts: figures (a and b) represent Ch A positive cells
(arrows) in H-727 and H-720 xenografts, respectively; (c and d) represent the number of Ch A positive cells for H-727 and H-720
xenografts, respectively, p < 0.05 (*), p < 0.01 (**) and p < 0.0001 (****).
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Figure 6 AZ and SFN Trytophan Hydroxylase (TPH) in Lung Carcinoid Xenografts: figures (a and b) represent TPH positive cells (arrow)
in H-727 and H-720 xenografts, respectively; (d) represent positive control (fetal lung tissue); (c and e) represent the number of TPH
positive cells for H-727 and H-720 xenografts, respectively; p < 0.01 (**), p < 0.001 (***) and p < 0.0001 (****).
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Table 2 The Percentage of Dense-Core Vesicles (DCV) after Treatment with AZ and/or SFN Compare to untreated group
in H-727 and H720 xenografts, respectively
Cell type Treatment % Reduction of DCV compared to control * P-value † P-value
H727 AZ 33 +/− 2.5 p < 0.05 p < 0.01
SFN 58 +/− 0.8 p < 0.001 p < 0.05
AZ + SFN 79 +/− 2.3 p < 0.001 -
H720 AZ 24 +/− 1.7 - p < 0.01
SFN 48 +/− 2.5 - p < 0.01
AZ + SFN 70 +/− 1.8 p < 0.01 -
* P-value was measured by comparing treated tumor to an untreated tumor.
† P-value was measured by comparing single agent treatment to a combination treatment.
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its survival pathways. We believe that AZ and SFN are
appropriate drug candidates because of their proven po-
tential to inhibit the survival pathways in other cancers.
High expressions of CAs have been reported in ileal
carcinoids [9]. In our original studies, we found that gas
sensing (chemo sensing) by pulmonary neuroendocrine
cells is an essential function especially in the neonatal
period [39]. Furthermore, we learned that lung carcinoid
cells produce CAs (manuscript in preparation). AZ is a
pan-CA inhibitor which has demonstrated anti-invasive
properties against renal cancer cell lines [41]. In other
cancers, SFN has demonstrated the potential to inhibit
survival pathways, which are also involved in carcinoids.
Thus, SFN is reported to affect survival pathway by
hyperphosphorylation of Rb protein in colon cancer
cells, which is anti-apoptotic in unphosphorylated form
[22]. It was shown in previous study that SFN has
inhibited cyclin D1 in pancreatic cancer cells [23], while
cyclin D1-induced Rb overexpression has been found to
be upregulated in pulmonary carcinoids [24]. SFN is also
an inhibitor of histone deacetylases (HDAC) [25] andFigure 7 AZ and SFN Affect Invasive Activity in the H-727 Lung Carcin
activity of AZ and/or SFN in H-727 xenografts cells. Invasive assay was
treatment of NOD/SCID mice with AZ and/or SFN, 20 mg/kg and/or 40 mgother HDAC inhibitors such as valproic acid and
suberoyl bis-hydroxamic acid in combination with lith-
ium have demonstrated significant growth inhibition and
cell cycle arrest in H-727 cells [26]. We have showed
that SFN alone is effective in inhibiting in vitro and
in vivo tumor growth. At higher doses, SFN causes cell
cycle arrest and differentiation when used against an-
other aggressive pediatric cancer, neuroblastoma (manu-
script in preparation). Therefore, it is reasonable to
consider that the combination of AZ and SFN can be in-
vestigated for its ability to inhibit the growth and inva-
sive potential of advanced stage carcinoids.
In the present study, both AZ and SFN reduced the
viability and clonogenicity of H-727 and H-720 car-
cinoid cell lines in a dose-dependent manner, in vitro.
Both agents delayed tumor growth by reducing the
invasive fraction of carcinoid cells and the 5-HT con-
tent of tumor. AZ and/or SFN inhibited the autocrine
growth effects of 5-HT in a dose-dependent manner.
The combination of AZ and SFN demonstrated sig-
nificant advantage over both as single agents in all
respects.oid Xenografts: figures (a and b) represent the anti-invasive
performed in lung carcinoid tumor cells (H-727 xenografts) after
/kg, respectively for 14 days, p < 0.05 (*) and p < 0.0001 (****).
Table 3 The percentage of invasive fraction of tumor cells after treatment with AZ and/or SFN within H-727 xenografts
Cell Type Treatment % Invasive cells fraction * P-value † P-value
H727 AZ 26 +/− 6.1 - p < 0.0001
SFN 39 +/− 3.2 p < 0.05 p = 0.002
AZ + SFN 69 +/− 5.3 p < 0.0001 -
* P-value was measured by comparing treated tumor cells to untreated tumor cells.
† P-value was measured by comparing single agent treatment to a combination treatment.
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cinoid cells by both single agents indicates that the sig-
nificant advantage of combination would be an additive
or synergistic effect rather than potentiation. Previously,
SFN in combination with cisplatin, gemcitabine, doxo-
rubicin and 5-flurouracil has been reported to reduce
the clonogenicity of pancreatic and prostatic cancer cells
[42]. Here, the IC50 of AZ and SFN was higher for ac-
tively proliferating normal cells FLF, indicating lower
susceptibility of normal tissues to our drugs, unlike con-
ventional cytotoxic agents. This could be due to the
targeted mechanism of action of our drugs on specific
pathways, which are active in carcinoids and are criticalFigure 8 AZ and SFN Treatment Reduce Serotonin Content in
the H-727 and H-720 Lung Carcinoid Xenografts: figures (a and
b) represent the amount of 5-HT in nmol/mg measured by
LC-MS in H-727 and H-720 xenografts; untreated versus
treatments for 14 days in lung carcinoid tumor cells after
treatment of NOD/SCID mice with AZ and/or SFN, 20 mg/kg
and/or 40 mg/kg, respectively; *(p < 0.05), **(p < 0.01),
***(p < 0.001) and ****(p < 0.0001).for the survival and proliferation of carcinoid cells.
PI3K/AKT/mTOR pathway is upregulated in H-727 and
H-720 cell lines and these cells have reported to be sen-
sitive to mTOR inhibitors [43-45]. In GI carcinoids, Raf/
MEK/ERK pathway is reported to be active. SFN is
reported to inhibit Akt/mTor and MEK/ERK/pathways
in cancer cells [46,47]. Also, both MEK/ERK and PI3K/
AKT pathways are known to regulate the expression of
CAIX and these findings might be relevant when com-
bining an inhibitor of CAIX with SFN, which inhibits
these pathways [48,49].
The in vivo doses of AZ and SFN were selected on the
basis of their efficacies in previous studies. AZ (20 mg/
Kg) has demonstrated reduction in spontaneous lung
metastasis of lung carcinoma cells at a rate of 62% [50].
In another study, SFN (40 mg/Kg) significantly reduced
the tumor weights of orthotopic prostate cancer xeno-
grafts compared to untreated control [51]. In our study,
in vivo, AZ and SFN demonstrated antitumor efficacy as
single agents in both H-727 and H-720 xenografts, while
the combination had significantly higher antitumor effi-
cacy in both cases. The in vivo efficacy of AZ and SFN
in the mouse subcutaneous xenograft model is in agree-
ment with the in vitro data. In vitro clonogenicity assay
has been employed to predict the clinical efficacy of che-
motherapeutics. Moreover, the in vitro clonogenicity and
invasion assay demonstrates that SFN on it own was
more effective overall than AZ on its own. SFN showed
greater tumor reduction than AZ. Interestingly, the
in vivo results parallel the in vitro results in terms of
both the individual and combined drug treatments,
which perhaps suggests that the in vitro data may be
predictive of the in vivo results.
The indicators of cell death, including condensed nu-
clei, shrunken cells and apoptotic bodies, observed
under the electron microscope in this study, have been
used previously to evaluate the apoptotic effect of drug
treatment on gastric cancer xenografts [52]. In both H-
727 and H-720 xenografts, these effects were more pro-
nounced in the animals treated with the combination. In
addition, the electron microscopy results suggest that
the combined therapy is more effective at reducing the
formation of cytoplasmic dense-core vesicles, which are
known to harbor the 5-HT containing granules [53].
Molecule markers such as phospho-histone 3, Ki67
and ChA and TPH were used to examine the antitumor
Table 4 The percentage of 5-HT content of tumor cells within H-727 and H-720 Xenografts after treatment with AZ
and/or SFN
Cell Type Treatment % 5-HT content Compared to Control * P-value † P-value
H-727 AZ 22 +/− 1.2 p < 0.001 p < 0.01
SFN 14 +/− 2.7 p < 0.05 p < 0.05
AZ + SFN 59 +/− 7.9 p < 0.0001 -
H-720 AZ 19 +/− 9 p < 0.001 p < 0.0001
SFN 19 +/− 6.2 p < 0.001 p < 0.0001
AZ + SFN 45 +/− 3.4 p < 0.001 p < 0.0001
* P-value was measured by comparing treated tumor to untreated tumor.
† P-value was measured by comparing single agent treatment to a combination treatment.
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graft models. pHH3 serves as a marker of mitosis and
was used to determine the mitotic index in H-727 and
H-720 xenografts [54]. The mitotic index was signifi-
cantly reduced in all groups compared to the control.
The combination treated mice had a significantly lowerFigure 9 AZ and SFN Treatment Interfere with Exogenous 5-HT
Stimulated Growth of Lung Carcinoid Cells: figures (a, b)
represent AlamarBlue assay; dose response for AZ (black), SFN
(gray) and AZ + SFN (white) treatments of H-727 and H-720
cells (0–80 μM; 7 Days, 205% FBS) after adding 5-HT
exogenously into the culture medium, respectively; *(p < 0.05),
**(p < 0.01), ***(p < 0.001) and ****(p < 0.0001).mitotic index compared to either AZ or SFN treated
mice. Ki67, the proliferation marker, is associated with
low survival in patients with lung cancers, including TC
and AC [55]. We found that the proliferative index did
not change although the Ki67 staining intensity appeared
greater in all the treated animals. This might be expected
of cells that are arrested in the cell cycle since Ki67 is
expressed in all phases (variably) but not in G0. In the
present study, the reduction in the levels of ChA
upon treatment with AZ and/or SFN indicates the
antiserotonergic nature of the therapy [56].
After invasive assay, the cells that were characterized
as invasive were counted. These were then cultured and
passaged three times and stained with specific lung car-
cinoid marker (ChA) to confirm that the invasive cells
were originated from tumor cells and not the non-
cellular component of xenografts. The invasive H-727
xenograft cells phenotypically matched with H-727 cells
in monolayer culture with positive expression of ChA in
these cells. We observed that SFN caused reduction in
the invasive potential of cells isolated from H-727 xeno-
grafts, an effect which was significantly enhanced by the
combination. Although AZ alone did not affect the inva-
siveness of H-727 cells, it potentiated the anti-invasive
property of SFN. This finding is in agreement with pre-
vious reports where SFN inhibited the in vitro migration
of oral carcinoma cells by down regulation of MMP-1
and MMP-2 secretion and ovarian cancer cells by
increasing apoptotic cell death via an increase in Bak/
Bcl-2 ratio and cleavage of procaspase-9 and poly (ADP-
ribose)-polymerase (PARP) [57,58]. Since the 5-year
survival rate in metastatic bronchial carcinoids is only
20-30% [4], reduction in the invasive carcinoid cell
population upon in vivo AZ + SFN treatment indicates
its possible advantage in treating metastatic disease.
Since AZ and SFN can reduce the number of viable
carcinoid cells, we hypothesized that the treatment could
affect 5-HT content of the tumor. We observed a reduc-
tion in 5-HT content of tumor xenografts following the
treatment with AZ and/or SFN. The reduction of TPH
expression as observed by IHC corroborates with the
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sible mechanism by which AZ and/or SFN reduce 5-HT
levels. Inhibition of TPH as a means to reduce 5-HT
levels has been used in the case of LX1031, a novel drug
being investigated for managing carcinoid syndrome
[59]. However, no agent reducing TPH expression has
been reported for managing carcinoid syndrome. The
mechanism by which our drugs reduce TPH expression
can be speculated on the basis of previous reports.
HDAC has been implicated in the reduction of TPH ex-
pression in mood disorder patients [60,61]; therefore,
HDAC inhibition by SFN may have caused TPH reduc-
tion. Several factors can contribute to the synergistic ef-
fect on 5-HT reduction, including increased apoptosis of
5-HT producing carcinoid cells and the effect of CA in-
hibition on 5-HT production. Moreover, AZ and/or SFN
reduced 5-HT-induced in vitro proliferation of carcinoid
cells in the present study. Reduction in 5-HT content of
the tumor and the inhibition of 5-HT-mediated auto-
crine growth effects can be two possible mechanisms
contributing to increased antitumor efficacy by the com-
bination and can also manage carcinoid syndrome.
Conclusion
We show for the first time that the growth of bronchial
carcinoids is significantly inhibited in vitro and in vivo
by AZ and/or SFN treatment in a dose-dependent rela-
tionship. Furthermore, AZ and/or SFN treatment caused
a reduction in 5-HT content of the carcinoid cells both
in vitro and in vivo. The combination of the two agents
produced a more marked and efficacious effect than
did a single agent. Since the effective doses of single
agents and the combination are well within clinical
range and bioavailability, our results suggest a poten-
tial new therapeutic strategy for the treatment of
bronchial carcinoids.
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